Wang J S, Wang Z
Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Zhonghua Yi Xue Za Zhi. 2022 Jul 26;102(28):2137-2141. doi: 10.3760/cma.j.cn112137-20220605-01245.
Hemophagocytic lymphohistiocytosis is a rapidly progressive and highly fatal disease with no specific clinical manifestations and multiple potential etiologies. Timely initiation of appropriate treatment is the key to improvement of the prognosis. Timely, accurate, and complete diagnosis of hemophagocytic lymphohistiocytosis requires the three-step principle, which is suspected diagnosis, confirmed diagnosis, and etiological diagnosis. With the development of new diagnostic technologies and methods, the establishment of a standardized diagnostic system and the construction of clinical pathways for hemophagocytic lymphohistiocytosis, the diagnostic efficiency of the fatal disease has been continuously improved, and hemophagocytic lymphohistiocytosis has entered an era of standardized, path-based and individualized accurate diagnosis.
噬血细胞性淋巴组织细胞增生症是一种进展迅速且死亡率很高的疾病,没有特异性临床表现,病因多样。及时启动恰当治疗是改善预后的关键。噬血细胞性淋巴组织细胞增生症的及时、准确及完整诊断需要遵循三步原则,即疑似诊断、确诊及病因诊断。随着新诊断技术和方法的发展、噬血细胞性淋巴组织细胞增生症标准化诊断体系的建立以及临床路径的构建,这种致命疾病的诊断效率不断提高,噬血细胞性淋巴组织细胞增生症已进入标准化、基于路径及个体化精准诊断的时代。